PDF(Pubmed)
Abstract：
Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified as potent oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC). The discovery of ALK inhibition using a tyrosine kinase inhibitor (TKI) has dramatically improved the outcomes of patients with ALK-mutated NSCLC. However, the emergence of intrinsic and acquired resistance inevitably occurs with ALK TKI use. This review describes the molecular mechanisms of ALK TKI resistance and discusses management strategies to overcome therapeutic resistance.
摘要：
间变性淋巴瘤激酶（ALK）基因重排已被确定为几种恶性肿瘤中有效的致癌驱动因素。包括非小细胞肺癌（NSCLC）。使用酪氨酸激酶抑制剂（TKI）的ALK抑制作用的发现极大地改善了ALK突变的NSCLC患者的预后。然而,使用ALKTKI不可避免地出现内在和获得性抗性。这篇综述描述了ALKTKI耐药的分子机制，并讨论了克服治疗性耐药的管理策略。
